Abstract
Rapid diagnostic tests (RDTs) may improve the early detection of visceral leishmaniasis (VL), but their real-world performance requires additional study. Therefore, we evaluated the performance of an rK39-based RDT (Kalazar Detect™) for the detection of VL in an endemic, large urban area. Data were collected from a registry of rK39 RDT performed at 11 emergency care units in Belo Horizonte, Brazil, and from a national database of reportable communicable diseases of the Sistema de Informação de Agravos de Notificação (SINAN). The rapid rK39 test was performed in 476 patients, with 114 (23.9%) positive results. The analysis of rK39 RDT performance was based on 381 (80%) cases reported to the SINAN database, of which 145 (38.1%) were confirmed cases. Estimates for sensitivity and specificity were 72.4% (95% CI: 64.6-79%) and 99.6% (95%CI: 97.6-99.9%), respectively. Positive and negative predictive values were estimated at 99.1% (95%CI: 94.9-99.8%) and 85.5% (95%CI: 80.8-89.1%), respectively. In addition, close agreement between the rK39 RDT and indirect immunofluorescence was observed. In summary, the rK39 RDT showed a high specificity but only moderate sensitivity. In endemic areas for VL, treatment may be considered in cases with clinical manifestations and a positive rK39 RDT, but those with a negative test should be subjected to further investigation.
Highlights
Rapid diagnostic tests (RDTs) may improve the early detection of visceral leishmaniasis (VL), but their real-world performance requires additional study
This RDT provided by the Ministry of Health was marketed as Kalazar DetectTM (InBios International), an immunochromatographic test that provides the qualitative detection of antibodies against the recombinant K39 protein of Leishmania
Rapid diagnostic tests (RDTs) based on recombinant K39 (rK39) showed good accuracy for VL diagnosis when widely implemented in a large urban area
Summary
Rapid diagnostic tests (RDTs) may improve the early detection of visceral leishmaniasis (VL), but their real-world performance requires additional study. In endemic areas for VL, treatment may be considered in cases with clinical manifestations and a positive rK39 RDT, but those with a negative test should be subjected to further investigation. Visceral leishmaniasis (VL) has a wide global distribution, with 200,000 to 400,000 estimated cases per year[1], and is the second largest cause of death among parasitic diseases worldwide[2]. Belo Horizonte, a city of 2.4 million inhabitants located in the southeastern part of the country, reported a mean incidence of 5.2 cases/100,000 people during the same time period, with a case fatality rate of 13.4%5.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Revista da Sociedade Brasileira de Medicina Tropical
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.